Asia Pacific Cartilage Degeneration Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Procedure Type (Osteochondral Transplant, Chondroplasty, Joint Replacement, Meniscus Transplants, Cell-based Cartilage Resurfacing, and Others); Application (Knee, Hips and Others); and End User (Hospitals & Specialty Clinics, Ambulatory Surgical Centers and Academic & Research Institutes) and Country

Market Introduction

Degeneration of cartilage can lead to pain and chronic inflammation in joints of the human body. Furthermore, damaged cartilage can potentially influence the quality of a patient’s life. Continuous research and developments are innovating new techniques and methodologies to deal with damaged cartilages. A few of these techniques comprise joint replacement, cell therapies, and chondroplasty.

Market Overview and Dynamics

The Asia Pacific cartilage degeneration market is expected to reach US$ 2,509.24 million by 2027 from US$ 1,721.26 million in 2019; it is anticipated to grow at a CAGR of 5.0% from 2020 to 2027. The increasing prevalence of sports injuries and obesity is expected to boost the growth of the cartilage degeneration market in APAC. However, the market growth is impacted by the high cost of cartilage therapies.

Key Market Segments

In terms of procedure type, the joint replacement segment accounted for the largest share of the Asia Pacific cartilage degeneration market in 2019. In terms of application, the knee segment accounted for the largest share of the Asia Pacific cartilage degeneration market in 2019. In terms of end user, the hospitals and specialty clinics segment accounted for the largest share of the Asia Pacific cartilage degeneration market in 2019.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the Asia Pacific cartilage degeneration market are the World Health Organization (WHO), Indian Council of Medical Research (ICMR), National Center for Biotechnology Information (NCBI), and Australian Institute of Health and Welfare.

Reasons to buy report

• Understand the Asia Pacific cartilage degeneration market landscape and identify segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive market landscape in the region
• Efficiently plan mergers and acquisitions, and partnership deals in the APAC cartilage degeneration market by identifying segments with the most promising probable sales
• Take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segments
• Obtain revenue forecast for market based on various segments for the period 2019–2027

Asia Pacific cartilage degeneration market segmentation

By Procedure Type

• Joint Replacement
• Chondroplasty
• Cell-based Cartilage Resurfacing
• Osteochondral Transplant
• Meniscus Transplants
• Others

By Application

• Knee
• Hips
• Others

By End User

• Hospitals & Specialty Clinics
• Ambulatory Surgical Centers
• Academic & Research Institutes

By Country

• China
• Japan
• India
• South Korea
• Australia

Company Profiles

• B. Braun Melsungen AG
• Smith & Nephew
• Stryker Corporation
• CartiHeal, Inc
• Vericel Corporation

The List of Companies - Asia Pacific Cartilage Degeneration Market

1. B. Braun Melsungen AG
2. Smith & Nephew
3. Stryker Corporation
4. CartiHeal, Inc
5. Vericel Corporation

• Understand the Asia Pacific cartilage degeneration market landscape and identify segments that are most likely to guarantee a strong return.

• Stay ahead of the race by comprehending the ever-changing competitive market landscape in the region.

• Efficiently plan mergers and acquisitions, and partnership deals in the APAC cartilage degeneration market by identifying segments with the most promising probable sales.

• Take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segments.

• Obtain revenue forecast for market based on various segments for the period 2019–2027